Evergraf 0.5mg Tablet

Evergraf 0.5mg Tablet is an antineoplastic drug belonging to the class of mTOR kinase inhibitors, containing the active ingredient everolimus. It is commonly prescribed for advanced breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumours, and in the treatment of subependymal giant cell astrocytoma (tumours found in the ventricles of the brain). It is also used in certain cases of kidney transplant and other cancers. Good oral hygiene and regular dental check-ups are important during treatment since this medicine may cause sores or ulcers in the mouth. In some cases, it is combined with cyclophosphamide, an alkylating agent, to manage subependymal giant cell astrocytoma. The evergraf 0.5mg dosage must be followed exactly as prescribed by your healthcare provider. Before starting treatment, understand that your risk of bacterial or viral infections increases. If you have a history of Hepatitis B, Evergraf 0.5mg Tablet may increase the chances of reinfection. Inform your healthcare provider immediately if you experience fever, chills, cough, yellowing of the skin, joint pain, or swelling. Patients are advised to limit exposure to sunlight and UV light by wearing protective clothing and using sunscreen regularly, as Evergraf can increase the risk of developing skin cancers. Avoid grapefruit juice or grapefruit during treatment, as it can affect how the drug works. For patients considering treatment options, evergraf 0.5mg substitute medicines may be considered if advised by your doctor. Information regarding evergraf 0.5mg price, evergraf 0.5mg for cancer, and evergraf 0.5mg for kidney transplant should be discussed with your healthcare provider or pharmacist for proper guidance. You may also review evergraf 0.5mg tablet substitutes if recommended in your treatment plan.

Evergraf 0.5mg uses are Advanced breast cancer Advanced renal cell carcinoma Advanced pancreatic neuroendocrine tumours Treatment of subependymal giant cell astrocytoma

Evergraf 0.5mg tablet inhibits the activity of a protein called mammalian target of rapamycin (mTOR), which regulates cell growth. This drug can slow the growth of abnormal cancer cells by blocking the mTOR protein and helps to reduce the size of tumours and improve outcomes in patients.

Take the Evergraf 0.5mg tablet as advised by your physician. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Evergraf 0.5mg side effects are Serious Difficulty breathing, or swallowing Swelling of face, lips, tongue, throat Severe itching, red rash, raised bumps Common Infection (chills, increased temperature) Coughing Wheezing Excessive thirst High urine output or severely decreased urine output Tiredness Bleeding Increased appetite with weight loss

Risk to pregnancy : Evergraf 0.5mg Tablet may harm the unborn fetus. Inform your healthcare provider if you are pregnant or planning pregnancy. Pregnancy testing : A pregnancy test will be conducted before starting treatment. Birth control : Discuss effective contraceptive methods with your doctor and use them during treatment and for 8 weeks after your last dose. Breastfeeding caution : The medicine passes into breast milk, so breastfeeding is not recommended during treatment. Mouth ulcers : Occurrence of mouth ulcers or sores is common during this treatment. Mouthwash use : Your healthcare provider may prescribe a mouthwash—use it as recommended to prevent and manage these symptoms.